- President Trump threatens to not sign COVID-19 bill
- US Jobless claims rose less than expected
- Pfizer (PFE.US) will provide additional 100 million of its COVID-19 vaccine
US indices launched today's session higher after jobless claims rose less than expected last week. Upbeat news from the labour market overshadowed concerns over fresh stimulus and coronavirus spread. President Trump raised questions over whether he will sign the new aid-bill anytime soon. US President called the Covid relief bill an unsuitable “disgrace” and asked Congress to boost stimulus checks to $2,000 and remove unnecessary items.
US30 – index launched today’s session higher and is approaching the upper limit of the triangle pattern which coincides with the 50 SMA (green line). Should upbeat moods prevail, resistance at 30,319 pts may come into play. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appPfizer (PFE.US) and its partner BioNTech (BNTX.US) made a deal with the US government to provide 100 million additional doses of its Covid-19 vaccine, increasing the total that Pfizer has agreed to provide to 200 million. The extra 100 million doses will be delivered by the end of July.
Pfizer (PFE.US) stock launched today’s session higher after the company announced a second deal with the US government regarding Covid-19 vaccine. If the current sentiment prevails, the upward move could be extended to the $38.00 handle. On the other hand, if sellers will manage to regain control then another downward impulse towards $ 36.00 could be launched. Source: xStation5
Magna International (MGA.US) automotive supplier will join forces with South Korea’s LG Electronics to build electric car components such as motors, inverters and on-board chargers.
Walmart (WMT.US) stock fell 1.2% on Tuesday after U.S. attorneys sued it for its alleged role in the opioid crisis. The company called the suit an attempt to deflect attention from shortcomings in government, notably in the DEA and Health departments.
AstraZeneca (AZN.US) announced its Covid-19 vaccine should be effective against the new strain of coronavirus, according to an the drugmaker's spokesman in an email to Reuters.
Merck (MRK.US) signed a deal with the US government to manufacture and supply its Covid-19 therapeutic known as MK-7110. Late-stage trial results earlier this year showed the treatment reduced the risk of death or respiratory failure by 50%, and as well as a 60% likelihood of clinical improvement.
